Trivalent Influenza Vaccine (Vanderbilt-Ingram Cancer Center)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTrivalent Influenza Vaccine (Vanderbilt-Ingram Cancer Center)
Drug Alias NameN/A
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Biological material > Viral vaccine
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsHematopoietic stem cell transplantation (HSCT)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVanderbilt-Ingram Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesVanderbilt-Ingram Cancer Center
Inactive CompaniesN/A
Active IndicationsHematopoietic stem cell transplantation (HSCT)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A